News and Events
Kalbe Launches Anemia Efepoetin Alfa, a Drug for Patients with Chronic Kidney Diseases
Through its subsidiaries of PT Kalbe Genexine Biologics (KGbio) and PT Finusolprima Farma Internasional (FIMA)...
Kalbe Launches Serplulimab, Lung Cancer Therapeutic Drug
PT Kalbe Farma Tbk (Kalbe) is currently the only domestic pharmaceutical company...
KGbio Received Market Approval for Efesa
PT Kalbe-Genexine Biologis (KGbio) received a distribution permit from BPOM for Efesa...
Kalbe Establishes Strategic Cooperation with Henlius for Lung Cancer Therapeutic Drug (Serplulimab) in the Middle East and North Africa Territories
PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe Genexine Biologics (KGbio)...
Press Conference on Rituxikal Distribution Permit Approval by BPOM
On 28 December 2022, BPOM has issued a distribution permit for Rituxikal as the first monoclonal antibody product...
Trazher 150 mg Powder for Concentrate for Solution for Infusion is approved in Singapore
On 19 Oct 2022, Trazher 150 mg Powder for Concentrate for...
Indonesia's FDA (BPOM) has approved new indication for Theracim
Indonesia’s FDA (BPOM) has approved new indication “Locally advanced non-nasopharyngeal...
Thailand FDA has approved Rituxikal (Rituximab Biosimilar)
On 11 May 2022, Thailand FDA has approved Rituxikal (Rituximab Biosimilar). By this milestone, ...
General Atlantic US Invests US$55 Million in Kalbe Genexine Biologics
General Atlantic, a leading worldwide growth equity firm that invests in and supports early-stage companies...